Claims for Patent: 9,532,989

Summary for Patent: 9,532,989

Title:	Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines
Abstract:	The present invention relates to compounds of Formula P-I ##STR00001## where the variables (e.g. R.sub.1, Y, A, R.sub.1, R.sub.a, R.sub.a\', R.sub.b, R.sub.b\', R.sub.c, R.sub.c\', R.sub.d, R.sub.d\', R.sub.e, or R.sub.e\') and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
Inventor(s):	Coller; Barry S. (New York, NY), Thomas; Craig (Rockville, MD), Filizola; Marta (New York, NY), McCoy; Joshua (Portland, ME), Huang; Wenwei (Rockville, MD), Shen; Min (Boyds, MD)
Assignee:	THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (New York, NY) THE ROCKEFELLER UNIVERSITY (New York, NY)
Application Number:	14/730,707
Patent Claims:	1. A method for the treatment of a thrombotic disorder comprising administering to a subject having a thrombotic disorder or at risk of thrombotic disorder an effective amount of a compound according to Formula P-I, in free or pharmaceutically acceptable salt form, or a pharmaceutical composition comprising a compound of Formula P-I and a pharmaceutically acceptable diluent or carrier, such that platelet aggregation and/or adhesion is reduced; wherein Formula P-I is: ##STR00081## wherein: i) A is S, N(H), CH.sub.2, or O; ii) R.sub.1 is: phenyl optionally substituted with one or more nitro, --C(O)N(R.sub.5)(R.sub.6) and/or --N(R.sub.5)(R.sub.6), and Y is a --C.sub.1-C.sub.4alkylene or arylene; phenyl substituted with one or more nitro and/or --N(R.sub.5)(R.sub.6), and Y is a single bond; phenyl substituted with --C(O)OR.sub.3 and Y is a --C.sub.1-C.sub.4alkylene or arylene; heteroaryl wherein said heteroaryl group is optionally substituted with one or more --C.sub.1-C.sub.4alkyl, and Y is a single bond or --C.sub.1-C.sub.4alkylene; heteroaryl wherein said heteroaryl group is substituted with halo, --C(O)OH, --CH.sub.2C(O)OH, or --NH.sub.2, and Y is arylene; pyrazolyl, isoxazolyl, furyl or thienyl and Y is arylene wherein said pyrazolyl, isoxazolyl, furyl or thienyl is optionally substituted with one or more --C.sub.1-C.sub.4alkyl, --C.sub.0-4alkyl-C(O)OH, --N(R.sub.13)(R.sub.14), or halo; or --C(O)N(R.sub.4)(CH.sub.2).sub.1-4--C(O)OR.sub.3 and Y is a single bond, --C.sub.1-C.sub.4alkylene or arylene, --C(O)N(R.sub.4)(CH.sub.2).sub.1-4--N(R.sub.13)(R.sub.14) and Y is a single bond, --C.sub.1-C.sub.4alkylene or arylene; --N(R.sub.4)--C(O)-heteroaryl wherein said heteroaryl is optionally substituted with halo and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.4)--C.sub.1-4alkylene-heteroaryl and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.10)--C(O)--[C(R.sub.11)(R.sub.12)].sub.1-4--N(R.sub.13)(R.sub.1- 4) and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.10)--C(O)--C.sub.3-10heterocycloalkyl and Y is a single bond, --C.sub.1-C.sub.4alkylene or arylene; --N(R.sub.4)(CH.sub.2).sub.1-4--C(O)OR.sub.4 and Y is C.sub.1-C.sub.4alkylene or arylene; --N(R.sub.4)C(O)C(H)(NH.sub.2)CH.sub.2CH.sub.2--C(O)OR.sub.3 and Y is arylene; --N(R.sub.4)C(O)C(H)(NH.sub.2)CH.sub.2-heteroaryl and Y is arylene; --N(R.sub.4)C(O)C(H)(CH.sub.3)--NH.sub.2 and Y is arylene; --N(R.sub.4)C(O)CH.sub.2CH.sub.2C(H)(NH.sub.2)--COOH and Y is arylene; --N(R.sub.4)C(O)--C(H)(NH.sub.2)CH.sub.2CH.sub.2--COOH and Y is arylene; or --N(R.sub.4)C(O)-heteroaryl (--N(H)C(O)isoxazolyl) and Y is arylene; iii) R.sub.2 is H, halo or --C.sub.1-C.sub.4alkyl; iv) R.sub.a, R.sub.a', R.sub.b, R.sub.b', R.sub.c, R.sub.d, R.sub.d', R.sub.e, and R.sub.e' are independently H or C.sub.1-C.sub.4alkyl; v) R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently H or C.sub.1-C.sub.4alkyl; vi) R.sub.10, R.sub.11, R.sub.12, R.sub.13 and R.sub.14 are independently H or C.sub.1-4alkyl. 2. The method according to claim 1, wherein both platelet aggregation and adhesion are reduced. 3. The method of claim 1, wherein said thrombotic disorders is selected from a group consisting of stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery, peripheral vascular disease or thrombotic disorders resulting from atrial fibrillation or inflammation. 4. The method of claim 1, wherein said thrombotic disorder is thrombosis induced by peripheral vascular surgery. 5. The method of claim 1, wherein said Compound is: ##STR00082## in free or pharmaceutically acceptable salt form. 6. The method of claim 1, further comprising administering to the subject an effective amount of at least one therapeutic agent selected from a group consisting of anti-coagulant, antiplatelet, and fibrinolytic agents, in free or pharmaceutically acceptable salt form. 7. The method according to claim 6, wherein said therapeutic agent is selected from a group consisting of heparin, low molecular weight heparins, bivalirudin, Fondaparinux, warfarin, Acenocoumarol, Phenprocoumon, Phenindione, Abbokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide and tirofiban. 8. The method of claim 7, wherein said therapeutic agent is heparin. 9. The method of claim 1, wherein R.sub.1 is phenyl optionally substituted with one or more nitro or --N(R.sub.5)(R.sub.6) and Y is a --C.sub.1-C.sub.4alkylene or arylene; phenyl substituted with one or more nitro or --N(R.sub.5)(R.sub.6) and Y is a single bond; phenyl substituted with --C(O)OR.sub.3 and Y is a --C.sub.1-C.sub.4alkylene or arylene; heteroaryl wherein said heteroaryl group is optionally substituted with one or more --C.sub.1-C.sub.4alkyl and Y is a single bond, or --C.sub.1-C.sub.4alkylene; pyrazolyl, isoxazolyl, furyl or thienyl and Y is arylene wherein said pyrazolyl, isoxazolyl, furyl or thienyl is optionally substituted with one or more --C.sub.1-C.sub.4alkyl, --C.sub.0-4alkyl-C(O)OH, --N(R.sub.13)(R.sub.14), or halo; or --C(O)N(R.sub.4)(CH.sub.2).sub.1-4--C(O)OR.sub.3 and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --C(O)N(R.sub.4)(CH.sub.2).sub.1-4--N(R.sub.13)(R.sub.14) and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.4)--C(O)-heteroaryl wherein said heteroaryl is optionally substituted with halo and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.4)--C.sub.1-4alkylene-heteroaryl and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.10)--C(O)--C(R.sub.11)(R.sub.12)--N(R.sub.13)(R.sub.14) and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.10)--C(O)--C.sub.3-10heterocycloalkyl and Y is a single bond, --C.sub.1-C.sub.4alkylene, or arylene; --N(R.sub.4)(CH.sub.2).sub.1-4--C(O)OR.sub.4 and Y is C.sub.1-C.sub.4alkylene or arylene; --N(R.sub.4)C(O)C(H)(NH.sub.2)CH.sub.2CH.sub.2--C(O)OR.sub.3 and Y is arylene; --N(R.sub.4)C(O)C(H)(NH.sub.2)CH.sub.2-heteroaryl and Y is arylene; --N(R.sub.4)C(O)C(H)(CH.sub.3)--NH.sub.2 and Y is arylene; --N(R.sub.4)C(O)CH.sub.2CH.sub.2C(H)(NH.sub.2)--COOH and Y is arylene; --N(R.sub.4)C(O)--C(H)(NH.sub.2)CH.sub.2CH.sub.2--COOH and Y is arylene; --N(R.sub.4)C(O)-heteroaryl or (--N(H)C(O)isoxazolyl) and Y is arylene. 10. The method according of claim 1, wherein the compound of Formula P-I is: ##STR00083## wherein R.sub.1 is --N(R.sub.10)--C(O)--C(R.sub.11)(R.sub.12)--N(R.sub.13)(R.sub.14); R.sub.2 is H or halo; R.sub.a, R.sub.a', R.sub.b, R.sub.b', R.sub.c, R.sub.d, R.sub.d', R.sub.e, and R.sub.e' are independently H or C.sub.1-C.sub.4alkyl; R.sub.10, R.sub.11, R.sub.12, R.sub.13 and R.sub.14 are independently H or C.sub.1-4alkyl; in free or salt form. 11. The method of claim 1, wherein the compound of Formula P-I is a compound selected from any of the following: ##STR00084## ##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089## in free or salt form. 12. The method of claim 1, wherein the compound of Formula P-I is: ##STR00090## in free or salt form.

Details for Patent 9,532,989

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2030-07-16
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2030-07-16
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2030-07-16
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2030-07-16